Assembly Biosciences, Inc. (ASMB) vs DiaMedica Therapeutics Inc. (DMAC)

A side-by-side comparison of Assembly Biosciences, Inc. and DiaMedica Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ASMB vs DMAC

growth of $100 · dividends reinvested · last 10y
ASMB -76.4% (-13.4%/yr)DMAC +113.7% (+7.9%/yr)DMAC compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020182020202220242026$24$214
ASMB DMAC

ASMB vs DMAC: by the numbers

  • •DMAC is the larger company ($454M vs $451M market cap).

Metrics side by side

Valuation

MetricASMBDMAC
P/E ratio41.35N/A
P/S ratio6.02N/A
P/B ratio1.4711.83

Profitability

MetricASMBDMAC
Gross margin99.82%0.00%
Operating margin-11.75%0.00%
Net margin-0.06%0.00%
ROE-0.01%-97.92%
ROIC-2.86%-100.87%

Growth (annualized)

MetricASMBDMAC
Revenue CAGR (5Y)-1.78%N/A
Total return CAGR (5Y)-10.66%16.41%

Frequently asked

How have ASMB and DMAC total returns compared?
Over the past 10 years, ASMB delivered -13.41% and DMAC delivered 7.89% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.